Saturday, November 09
|
Session Title |
Speaker(s) |
Primary Track |
Presentation Format |
7:30 AM - 8:00 AM
|
Opening Ceremony and Welcome Announcements
Speakers:
Todd A. Mahr, MD, FACAAI
David R. Stukus, MD, FACAAI
Mrs. Patricia Wedner, Alliance President
The 2019 Gold Headed Cane Award will be presented at this time to Dana V. Wallace, MD, FACAAI. |
|
Speaker:
Todd A. Mahr, MD, FACAAI
Speaker:
David R. Stukus, MD, FACAAI
|
|
Plenary Session
|
8:00 AM - 9:30 AM
|
PRESIDENTIAL PLENARY: Adapting to New Evidence
This session will address the evolution of evidence pertaining to conditions for which allergists play a central role in management. Attendees will hear discussion surrounding new guidelines, new conditions and new approaches to longstanding beliefs.
Moderator: Todd A. Mahr, MD, FACAAI, ACAAI President
8:00 am
Welcome and Introductions
Todd A. Mahr, MD, FACAAI, ACAAI President
8:02 am
Edward J. O'Connell Tribute
Susan Rudd Bailey, MD, FACAAI
8:05 am – Edward J. O'Connell Memorial Lecture
GRADEing Eosinophilic Esophagitis: What Is the Role of the Allergist?
Matthew Rank, MD, FACAAI
8:30 am
Alpha-gal: A Fascinating and Evolving Story
Michael Levin, MD, PhD, FACAAI
9:00 am
Asthma: Inflammation Is the Symptom, Not the Cause
Stephen Holgate, MD, FACAAI
|
|
Moderator:
Todd A. Mahr, MD, FACAAI
Facilitator:
Susan R. Bailey, MD, FACAAI
Speaker:
Matthew Rank, MD, FACAAI
Speaker:
Michael Levin, MD, PhD, FACAAI
Speaker:
Stephen Holgate, MD, FACAAI
|
Food & Drug Allergy and GI Disorders
|
Plenary Session
|
9:00 AM - 4:30 PM
|
Exhibit Hall Open
|
|
|
|
College Resource Center Open in Exhibit Hall
|
|
|
|
9:30 AM - 10:00 AM
|
Refreshment Break in Exhibit Hall
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. |
|
|
|
|
9:35 AM - 10:00 AM
|
Product Theater 1: Thinking Differently About Asthma Management: Revisiting a Window of Opportunity
Supported by AstraZeneca
Not For Credit
Presented by:
Reynold A Panettieri, MD
This program will examine the relationship between shortacting 2-agonist (SABA) reliance, patient behavior, and asthma morbidity. An understanding of SABA reliance and its consequences highlights an unmet need and an opportunity to optimize control.
Also visit AstraZeneca at Booth #301. |
|
|
|
|
Product Theater 2: A Path to Asthma Control
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Not For Credit
Presented by:
Neal Jain, MD
Listen to an expert clinician discussion an add-on maintenance treatment for patients with moderateto- severe asthma aged 12 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma. Our presenter will highlight key roles for Type 2 Inflammation in the pathobiology of asthma and the efficacy and safety data across three clinical trials in nearly 3,000 patients with asthma. Additionally, our presenter will lead an interactive discussion of different patient types who might be eligible for treatment.
Also visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313. |
|
|
|
|
Product Theater 3: Advancing the Treatment of Eosinophilic Disease
Supported by GlaxoSmithKline
Not For Credit
Presented by:
Dennis K. Ledford, MD
Join us for an engaging program exploring the role of eosinophils in disease management. We will examine key efficacy and safety data for a treatment that reduces eosinophils, including long-term data in patients with severe asthma. We will also discuss clinical approaches for identifying appropriate patient types that may benefit from a targeted treatment to reduce eosinophils.
Also visit GlaxoSmithKline at Booth #1012. |
|
|
|
|
10:00 AM - 11:30 AM
|
Ensuring the Success of Academic Allergy (Invitation Only)
Invitation only. All division directors and training program directors are invited.
This panel discussion is a program of the Joint Task Force on Academic Allergy/Immunology, which was created to evaluate needs and develop tools and strategies to support the success of academic allergy/immunology divisions. The interactive session will discuss challenges and opportunities facing A/I divisions within academic medical centers. There will be opportunity for significant audience involvement to discuss challenges, successes and opportunities at your center with other academic leaders.
Moderator: Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD
10:00 am
Welcome and Introductions
Bryan L. Martin, DO, FACAAI
Aidan A. Long, MD
10:05 am
Task Force Update
Bryan L. Martin, DO, FACAAI
Aidan A. Long, MD
10:30 am
Financing Within the Academic Allergy Division
Kevin J. Kelly, MD, FACAAI
11:00 am
Mentorship in Academic Allergy / Immunology
James T. Li, MD, PhD, FACAAI
11:25 am
Questions and Discussion
|
|
Moderator:
Bryan L. Martin, DO, FACAAI
Moderator:
Aidan A. Long, MD
Speaker:
Bryan L. Martin, DO, FACAAI
Speaker:
Aidan A. Long, MD
Speaker:
James T. Li, MD, PhD, FACAAI
Speaker:
Kevin Joseph Kelly, MD
|
Other
|
Symposium
|
Practical Use and Effectiveness of New Digital Health Technologies in Effective Treatment of Asthma
Supported by an independent educational grant from Teva Pharmaceuticals
Despite advances in pharmaceutical management of asthma, patients continue to have high frequency of health care utilization due to poor control of asthma symptoms and frequent exacerbations. Many factors are thought to contribute to this, with poor adherence to medical treatment felt to be a major factor. Adherence to asthma medications has historically been very poor, particularly with inhaled medications. Also, poor recognition of symptoms has frequently been found in a subset of patients with chronic asthma, leading to poor outcomes. Digital technology has the opportunity to address many of these issues. Mobile apps are being developed specifically for patients with asthma, including both educational and self- and remote-monitoring functions. New inhalers are being developed that contain chips to provide real-time feedback at the time of use. Digital technology has the opportunity to reduce health and social inequities incurred by the disease.
Moderators: Jared Darveaux, MD, and Mark C. Stahl, DO, FACAAI
10:00 am
Welcome and Introductions
Jared Darveaux, MD
Mark C. Stahl, DO, FACAAI
10:05 am
The Spectrum of Digital Health Offerings for Asthma
Bruce Bender, PhD
10:35 am
What Does the Evidence Show?
William C. Anderson, MD
11:05 am
Ready for Prime Time?
Nabeel Farooqui, MD, FACAAI
|
|
Moderator:
Jared Darveaux, MD
Moderator:
Mark C. Stahl, DO, FACAAI
Speaker:
Bruce Bender, PhD
Speaker:
William C. Anderson, MD
Speaker:
Nabeel Farooqui, MD, FACAAI
|
Asthma and Respiratory / Sleep Disorders
|
Practical Applications at Work Seminar
|
Prevention of Allergic Conditions: What Conversations to Have With Expecting Parents
ARS
Multiple new studies have been published that show the potential benefit of specific interventions in preventing the development of atopic dermatitis and food allergies. Allergists need to remain at the forefront of this research and understand how to implement evolving data into clinical practice. This session will utilize case-based discussions to review the most up-to-date evidence and provide practical talking points to help educate parents and primary care providers.
Moderators: Angela D. Hogan, MD, FACAAI, and Bruce J. Lanser, MD, FACAAI
10:00 am
Welcome and Introductions
Angela D. Hogan, MD, FACAAI
Bruce J. Lanser, MD, FACAAI
10:05 am
What the Latest Evidence Supports Regarding Early Life Interventions and the Prevention of Allergic Conditions
David M. Fleischer, MD, FACAAI
10:35 am
Let the Babies Eat: How to Discuss Introduction of Foods With Parents
Edmond S. Chan, MD
11:05 am
Probiotics, Prebiotics, Vitamin D and Fish Oil Supplements: How to Combat Misinformation Surrounding Allergy Prevention
Carina Venter, PhD, RD
|
|
Moderator:
Angela D. Hogan, MD, FACAAI
Moderator:
Bruce J. Lanser, MD, FACAAI
Speaker:
David M. Fleischer, MD, FACAAI
Speaker:
Edmond S. Chan, MD
Speaker:
Carina Venter, PhD, RD
|
Population Health and Infectious Diseases / International Travel
|
Clinical Conundrum
|
The Challenges of Infant Food Allergy and Anaphylaxis
Oral food challenges are the gold standard to diagnose food allergy. However, oral food challenges are underutilized in clinical practice. This session will address the challenges of implementing oral food challenges into clinical practice, with particular focus on performing food challenges in infants, as well as a review of anaphylaxis management in infants.
Moderators: Anne K. Ellis, MD, MSc, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI
10:00 am
Welcome and Introductions
Anne K. Ellis, MD, MSc, FACAAI
Matthew Greenhawt, MD, MSc, MBA, FACAAI
10:05 am
Best Practice for Oral Food Challenges – Which Patients Need a Challenge and When?
Justin C. Greiwe, MD, FACAAI
10:30 am
Practical Aspects of Infant Oral Food Challenges Suggested
Benjamin Prince, MD, MSci
10:55 am
Prevention and Management of Infant Anaphylaxis
Jay A. Lieberman, MD, FACAAI
11:20 am
Questions and Discussion
|
|
Moderator:
Anne K. Ellis, MD, MSc, FACAAI
Moderator:
Matthew Greenhawt, MD, MSc, MBA, FACAAI
Speaker:
Justin C. Greiwe, MD, FACAAI
Speaker:
Benjamin Prince, MD, MSci
Speaker:
Jay A. Lieberman, MD, FACAAI
|
Rhinitis / Sinusitis / Ocular and Anaphylaxis
|
Symposium
|
When Drugs Go Wild!
ARS MOC/CME
From skin-deep to outward, this session will discuss the etiology, management and evaluation of patients with severe cutaneous drug eruptions.
Moderators: Leonard Bielory, MD, FACAAI, and Joseph A. Bellanti, MD, FACAAI
10:00 am
Welcome and Introductions
Leonard Bielory, MD, FACAAI
Joseph A. Bellanti, MD, FACAAI
10:05 am
Reactions to Targeted Therapies and Immune Modulators
Mariana C. Castells, MD, PhD, FACAAI
10:35 am
Appearance and Recognition of Cutaneous Drug Eruptions
David A. Khan, MD, FACAAI
11:05 am
Approach to the Management and Treatment of Drug Eruptions
Aleena Banerji, MD
|
|
Moderator:
Leonard Bielory, MD, FACAAI
Moderator:
Joseph A. Bellanti, MD, FACAAI
Speaker:
Mariana C. Castells, MD, PhD, FACAAI
Speaker:
David A. Khan, MD, FACAAI
Speaker:
Aleena Banerji, MD
|
Dermatology
|
Clinical Conundrum
|
11:30 AM - 12:00 PM
|
Visit Exhibits / Lunch on Own
|
|
|
|
11:30 AM - 1:00 PM
|
Allied Health Professionals Luncheon
Supported by Aimmune Therapeutics
Not For Credit |
|
|
|
|
E-posters – Meet the Authors: Session 2
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Not For Credit |
|
Moderator:
Brian T. Kelly, MD, MA
|
|
|
GME Program Directors Committee Luncheon
|
|
|
|
11:30 AM - 3:00 PM
|
Doctors’ Job Fair
Not For Credit
Looking for new opportunities, an associate for your group or a buyer for your practice? The Doctors’ Job Fair brings together all interested parties seeking or offering professional opportunities. |
|
|
|
|
11:35 AM - 1:00 PM
|
Product Theater 1: Severe Eosinophilic Asthma: Case Studies with a Targeted Treatment Approach
Supported by AstraZeneca
Not For Credit
Presented by:
Warner Carr, MD
Please join us to learn more about ways to help identify eosinophilic asthma through a combination of clinical features, patient history and measurements of eosinophils told through three compelling patient case studies. Hosted by a national expert, explore a targeted treatment approach for patients with both efficacy and safety profile data.
Also visit AstraZeneca at Booth #301. |
|
|
|
|
Product Theater 2: Experience That Matters: Learn About the Possibility of Hereditary Angioedema (HAE) Patients Reducing Their Attack Rate to One a Year
Supported by CSL Behring
Not For Credit
Presented by:
Raffi Tachdjian , MD, MPH
Zahra Khan (HAE Patient Advocate)
Join us as we present newly published data from the Open Label Extension Study following patients long term. Hear from an HAE opinion leader and an HAE patient as they talk about the impact of HAE and successfully managing the disease.
Also visit CSL Behring at Booth #123. |
|
|
|
|
Product Theater 3: Immune Response Pathways: Characteristics of Asthma and Comorbidities
Supported by Novartis Pharmaceuticals Corporation
Not For Credit
Allergic asthma is a specific phenotype of a common disease with wide heterogeneity. Associated comorbidities often go hand-in-hand with the condition. Such comorbidities may share common immunopathological mechanisms with asthma that can influence its control. Immune Response Pathways: Characteristics of Asthma and Comorbidities will focus on the immune response of allergic asthma, accurate recognition of these characteristics and proper management of comorbidities.
Also visit Novartis Pharmaceuticals Corporation at Booth #1213. |
|
|
|
|
11:45 AM - 12:45 PM
|
Building ABAI Continuing Certification Together (non-CME)
Not For Credit
ACAAI, ABAI and diplomates are key stakeholders in the current transformation of allergy/immunology continuing certification. This session will provide attendees an overview of the current landscape of continuing board certification, an update on the continuous assessment program (CAP) and personal progress meter. An interactive town hall will be held during this session, as part of ABAI’s commitment to co-development of specialty-continuing certification.
Welcome and Introductions
Michael Nelson, MD, PhD, FACAAI
ABMS, ABAI, the Vision Commission and What It Means to You
Michael Nelson, MD, PhD, FACAAI
CAP Pilot Update and Progress Meter
Kathleen May, MD, FACAAI
Rayne Harrison
Cecelia MacCormack
Town Hall: Building Continuous Certification Together
Audience participation
Theodore Freeman, MD, FACAAI
Michael Nelson, MD, PhD, FACAAI
ABAI Directors |
|
|
|
|
1:00 PM - 2:30 PM
|
Advances in the Care of Patients With Common Variable Immune Deficiency (CVID)
We have an expanding supply of tools for managing the noninfectious complications of CVID. Understanding the availability and utility of these tools will help practitioners in the diagnosis and treatment of the noninfectious complications of CVID.
Moderators: Nikita Raje, MD, FACAAI, and Benjamin Prince, MD, MSci
1:00 pm
Welcome and Introductions
Nikita Raje, MD, FACAAI
Benjamin Prince, MD, MSci
1:05 pm
Medical Knowledge – Lung Disease in CVID
John M. Routes, MD, FACAAI
1:30 pm
Genetic Testing and Treatment
Lisa R. Forbes, MD
1:55 pm
Best Practices in Patient Care
Elena E. Perez, MD
2:20 pm
Questions and Discussion
|
|
Moderator:
Nikita Raje, MBBS, MSc
Moderator:
Benjamin Prince, MD, MSci
Speaker:
John M. Routes, MD, FACAAI
Speaker:
Lisa R. Forbes, MD
Speaker:
Elena E. Perez, MD
|
Clinical Immunology and Autoimmune and Biologicals
|
Symposium
|
Evolution of Food Allergy Therapies
MOC/CME
Several new interventions are likely to be approved by the FDA in the upcoming year. These therapies have different levels of efficacy and side effects and will likely greatly impact office flow. Thus, it is imperative that allergists become more facile with their knowledge regarding these therapies.
Moderators: John J. Oppenheimer, MD, FACAAI, and Marcus Shaker, MD, MSc, FACAAI
1:00 pm
Welcome and Introductions
John J. Oppenheimer, MD, FACAAI
Marcus Shaker, MD, MSc, FACAAI
1:05 pm
Efficacy and Safety of OIT and EPIT
J. Andrew Bird, MD, FACAAI
1:30 pm
Practical Impediments to These New Therapies
Julie Wang, MD, FACAAI
1:55 pm
Food Immunotherapy 2.0: What the Future May Hold
Brian P. Vickery, MD
2:20 pm
Questions and Discussion
|
|
Moderator:
John J. Oppenheimer, MD, FACAAI
Moderator:
Marcus Shaker, MD, MSc, FACAAI
Speaker:
J. Andrew Bird, MD, FACAAI
Speaker:
Julie Wang, MD, FACAAI
Speaker:
Brian P. Vickery, MD
|
Immunotherapy and Diagnostics
|
Symposium
|
Integrative Approaches to Office Health: Improving Patient Outcomes
The healthy allergy and immunology clinic involves more than just keeping the schedule full. An unhealthy clinic can contribute to the allergist’s stress level, burnout and depression, as well as poor patient satisfaction, compliance and outcomes. In this session, find out what constitutes an unhealthy work environment in the clinic and learn how to use the principles of integrative medicine to improve the health of the clinic and, consequently, of our patients and ourselves as providers.
Moderators: Janna M. Tuck, MD, FACAAI, and Meagan W. Shepherd, MD, FACAAI
1:00 pm
Welcome and Introductions
Janna M. Tuck, MD, FACAAI
Meagan W. Shepherd, MD, FACAAI
1:05 pm
Define and Outline the Unhealthy A/I Clinic and Its Impact on the Provider, Office Staff and Patient
Maeve E. O'Connor, MD, FACAAI
1:30 pm
Application of Integrative Medicine Principles in A/I Practice That Improve Office Health and Bring Better Patient Outcomes
Randy J. Horwitz, MD, PhD
1:55 pm
MBSR and Breath Work Applications for You and Your Patient
James Carmody, PhD
2:20 pm
Questions and Discussion
|
|
Moderator:
Janna M. Tuck, MD, FACAAI
Moderator:
Meagan W. Shepherd, MD, FACAAI
Speaker:
Maeve E. O'Connor, MD, FACAAI
Speaker:
Randy J. Horwitz, MD, PhD
Speaker:
James Carmody, PhD
|
Environmental and Integrative Medicine
|
Practical Applications at Work Seminar
|
New Frontiers: COPD, ACO and Adults With Wheezing
COPD is the third leading cause of death in the United States, and our specialty is encountering both diagnosed and undiagnosed COPD patients at an increased rate. Allergy/immunology specialists are in a unique position to be at the forefront of COPD care, including evaluating potential immune deficiencies in this patient population. In addition, many patients may have asthma-COPD overlap (ACO), and there is still considerable debate in the medical community regarding the exact diagnosis and treatment of this condition.
Moderators: Anil Nanda, MD, FACAAI, and Michael B. Foggs, MD, FACAAI
1:00 pm
Welcome and Introductions
Anil Nanda, MD, FACAAI
Michael B. Foggs, MD, FACAAI
1:05 pm
COPD GOLD Guidelines for the Allergist / Immunologist
William J. Calhoun, MD, FACAAI
1:30 pm
Diagnosis and Treatment of ACO: What Is Known and What Is New
Nicola A. Hanania, MD, MS
1:55 pm
What's Left: Other Causes of Wheezing in Adults
Mario Castro, MD, MPH
2:20 pm
Questions and Discussion
|
|
Moderator:
Anil Nanda, MD, FACAAI
Moderator:
Michael B. Foggs, MD, FACAAI
Speaker:
William Calhoun, MD, FACAAI
Speaker:
Nicola A. Hanania, MD, MS
Speaker:
Mario Castro, MD, MPH
|
Asthma and Respiratory / Sleep Disorders
|
Symposium
|
Racial, Ethnic and Socioeconomic Disparities in Food Allergy
This session will provide the allergist/immunologist a perspective on the diversity of food allergy along racial, ethnic and socioeconomic lines. There will be particular focus on associations with morbidity and mortality, what diverse families may value regarding food allergy, how they may choose to spend their health care dollars and how this may differ from the primarily white, middle class families typically described in food allergy.
Moderators: Cherie Y. Zachary, MD, FACAAI, and Princess Ogbogu, MD, FACAAI
1:00 pm
Welcome and Introductions
Cherie Y. Zachary, MD, FACAAI
Princess Ogbogu, MD, FACAAI
1:05 pm
Does Food Allergy Disproportionately Affect Particular Races or Ethnicities?
Ruchi Gupta, MD, MPH
1:30 pm
What Is the Socioeconomic Burden of Food Allergy Among Racially and Ethnically Diverse Populations?
Rachel Peters, MD, MPH, PhD
1:55 pm
Is There Racial and Ethnic Disparity in What Families Value Regarding Food Allergy?
Michael Levin, MD, PhD, FACAAI
2:20 pm
Questions and Discussion
|
|
Moderator:
Cherie Y. Zachary, MD, FACAAI
Moderator:
Princess Ogbogu, MD, FACAAI
Speaker:
Ruchi Gupta, MD, MPH
Speaker:
Rachel Peters, MPH, PhD
Speaker:
Michael Levin, MD, PhD, FACAAI
|
Food & Drug Allergy and GI Disorders
|
Symposium
|
The Changing Face of an Allergy Practice
Limit 45. Seats Available on first-come, first-served basis.
These expert round table discussions will address some of the threats and potential pitfalls of allergy practice today. Choose three of the five topics and spend 25 minutes with each expert addressing a phase of allergy practice. The expert will give a five-minute overview of the topic and will then answer questions and facilitate discussion with the table participants for 20 minutes.
Table Rotations: 1:05 pm, 1:30 pm, 2:00 pm
Moderator: Warner W. Carr, MD, FACAAI
1:00 pm
Welcome and Introductions
Warner W. Carr, MD, FACAAI
Table 1
Safeguarding Your Patient Data
James M. Tracy, DO, FACAAI
Table 2
Safeguarding Your Online Reputation
Melinda M. Rathkopf, MD, FACAAI
Table 3
Branding and Marketing
Stanley M. Fineman, MD, MBA, FACAAI
Table 4
USP
James L. Sublett, MD, FACAAI
Table 5
Financial Benchmarking
Kevin P. McGrath, MD, FACAAI
|
|
Moderator:
Warner W. Carr, MD, FACAAI
Speaker:
James M. Tracy, DO, FACAAI
Speaker:
Melinda M. Rathkopf, MD, FACAAI
Speaker:
Stanley M. Fineman, MD, MBA, FACAAI
Speaker:
James L. Sublett, MD, FACAAI
Speaker:
Kevin P. McGrath, MD, FACAAI
|
Practice Management / Professional Issues
|
Ask the Expert Roundtables
|
2:30 PM - 3:00 PM
|
E-posters – Meet the Authors: Session 3
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Not For Credit |
|
Moderator:
Brian T. Kelly, MD, MA
|
|
|
Cookies and Refreshment Break in Exhibit Hall
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. |
|
|
|
|
2:35 PM - 3:00 PM
|
Product Theater 1: XHANCE®: A Case-based Approach to Treatment
Supported by Optinose
Not For Credit
Presented by:
Shahnaz Fatteh, MD
Explore a unique patient case to understand how XHANCE is a different treatment approach.
Also visit Optinose at Booth #1021.
|
|
|
|
|
Product Theater 2: Inflammation and Disease Pathophysiology of Chronic Rhinosinusitis with Nasal Polyps
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Not For Credit
Presented by:
Eli O. Meltzer, MD
Please join Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. for a Product Theater presentation at the ACAAI Conference, located on the exhibit floor. Food and beverage to be served.
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., Booth #313 |
|
|
|
|
3:00 PM - 4:30 PM
|
Cannabis in 2019: Navigating Our Patients Through Facts and Misconceptions
ARS
This session will address cannabis legalization and patient perceptions and patterns of use. We will discuss how cannabis is commonly used, review the importance of asking our patients about cannabis use, the effects of cannabis on the lungs (also versus tobacco) and review allergic sensitization to cannabis. Common misconceptions will be discussed, including the ideas that cannabis is “good” for asthma, that it is safer than tobacco, that it is not addictive and that cannabis allergy does not exist. Attendees will gain a greater understanding of cannabis and its effects, so they can instantly bring this knowledge to their clinical practice in order to empower their patients and advocate for their well-being.
Moderators: William S. Silvers, MD, FACAAI, and Michael R. Rupp, MD, FACAAI
3:00 pm
Welcome and Introductions
William S. Silvers, MD, FACAAI
Michael R. Rupp, MD, FACAAI
3:05 pm
Introduction to Cannabis; Its Legalization, Patient Perceptions, Patterns of Use and Common Misconceptions
David R. Naimi, DO
3:35 pm
The Effects of Cannabis on the Lungs
Rohit K. Katial, MD, FACAAI
4:05 pm
Allergic Sensitization to Cannabis
Hannelore A. Brucker, MD, FACAAI
|
|
Moderator:
William S. Silvers, MD, FACAAI
Moderator:
Michael R. Rupp, MD, FACAAI
Speaker:
David R. Naimi, DO
Speaker:
Rohit K. Katial, MD, FACAAI
Speaker:
Hannelore A. Brucker, MD, FACAAI
|
Environmental and Integrative Medicine
|
Clinical Conundrum
|
Coding and Governmental Regulations Update
This session will address relevant changes, modifications and implementation of CPT and ICD-10 coding for 2019 and the AMA’s outlook for medicine. This will be accomplished by practical case-based scenarios focused on how the change may affect the practice of allergy and clinical immunology. In addition, we’ll review the state of politics and the national perspective of medicine as seen through the eyes of the AMA. Finally, we’ll offer an update on the changing landscape on Capitol Hill as it relates to the current state of government.
Moderators: James M. Tracy, DO, FACAAI, and Stephen A. Imbeau, MD, FACAAI
3:00 pm
Welcome and Introductions
James M. Tracy, DO, FACAAI
Stephen A. Imbeau, MD, FACAAI
3:05 pm
Coding Update
Gary N. Gross, MD, FACAAI
3:30 pm
The National Landscape of Medicine as Seen Through the Eyes of the AMA
Susan Rudd Bailey, MD, FACAAI
3:55 pm
The Political World With a Changing US Congress
Bill Finerfrock
4:20 pm
Questions and Discussion
|
|
Moderator:
James M. Tracy, DO, FACAAI
Moderator:
Stephen A. Imbeau, MD, FACAAI
Speaker:
Gary N. Gross, MD, FACAAI
Speaker:
Susan R. Bailey, MD, FACAAI
Speaker:
Bill Finerfrock
|
Practice Management / Professional Issues
|
Symposium
|
Cough Across the Ages
Supported by an independent educational grant from Merck & Co., Inc.
Cough is one of the most common symptoms of patients seen by allergist/immunologists. Understanding the mechanisms that lead to cough is paramount. A new paradigm has emerged of patients with cough (neural) hypersensitivity that does not respond to asthma, rhinitis and/or GERD therapy. Allergists need to understand the different therapeutic agents and their mechanisms of action in all stages of cough.
Moderators: Jeremy S. Katcher, MD, FACAAI, and J. Wesley Sublett, MD, MPH, FACAAI
3:00 pm
Welcome and Introductions
Jeremy S. Katcher, MD, FACAAI
J. Wesley Sublett, MD, MPH, FACAAI
3:05 pm
Evaluation of a Child With Cough
Kevin R. Murphy, MD, FACAAI
3:30 pm
Not All That Coughs Is Asthma: Considerations for Adults
Alan B. Goldsobel, MD, FACAAI
3:55 pm
Treatment Options in Cough
Mandel R. Sher, MD, FACAAI
4:20 pm
Questions and Discussion
A recording of this session will be available after the Annual Meeting on the College Learning Connection. |
|
Moderator:
Jeremy S. Katcher, MD, FACAAI
Moderator:
J. Wesley Sublett, MD, MPH, FACAAI
Speaker:
Kevin R. Murphy, MD, FACAAI
Speaker:
Alan B. Goldsobel, MD, FACAAI
Speaker:
Mandel R. Sher, MD, FACAAI
|
Asthma and Respiratory / Sleep Disorders
|
Symposium
|
Difficult-to-control Atopic Dermatitis: Cutting Edge Science, Practical Pearls and Targeted Therapy
Supported by an independent educational grant from Abbvie
This session will consider treatment of the itch in persons with atopic dermatitis. Should allergists prescribe monoclonal antibodies or drugs that block neurotransmitters?
Moderators: Myron J. Zitt, MD, FACAAI, and Allison C. Ramsey, MD, FACAAI
3:00 pm
Welcome and Introductions
Myron J. Zitt, MD, FACAAI
Allison C. Ramsey, MD, FACAAI
3:05 pm
The Microbiome of the Skin and Atopic Dermatitis
Donald Y. Leung, MD, PhD, FACAAI
3:30 pm
Atopic Dermatitis in Patients of Color
Andrew Alexis, MD, MPH
3:55 pm
The Treatment Options to Control Atopic Dermatitis
Mark Boguniewicz, MD, FACAAI
4:20 pm
Questions and Discussion
|
|
Moderator:
Myron J. Zitt, MD, FACAAI
Moderator:
Allison C. Ramsey, MD, FACAAI
Speaker:
Donald Y. Leung, MD, PhD, FACAAI
Speaker:
Andrew Alexis, MD, MPH
Speaker:
Mark Boguniewicz, MD, FACAAI
|
Dermatology
|
Symposium
|
The Updated EoE Guidelines – Whose Disease Is It Anyway?
This session will review the newly published jointly developed AGA/AAAAI/ACAAI GRADE-based EoE guidelines discussing the new clinical recommendations and areas of emerging evidence. There will be particular emphasis on how the allergist and gastroenterologist can co-manage this illness.
Moderators: John J. Oppenheimer MD, FACAAI, and Dana V. Wallace, MD, FACAAI
3:00 pm
Welcome and Introductions
John J. Oppenheimer MD, FACAAI
Dana V. Wallace, MD, FACAAI
3:05 pm
Out With the Old, In With the New – Key Guideline Updates to Managing the Patient With EoE
Matthew Greenhawt, MD, MSc, MBA, FACAAI
3:30 pm
Diet Versus Steroid – Choosing the Right Therapy
Matthew Rank, MD, FACAAI
3:55 pm
One Ring to Rule Them All – Approaches for How the Allergist and Gastroenterologist can Co-manage EoE
Edmond S. Chan, MD
4:20 pm
Questions and Discussion
|
|
Moderator:
John J. Oppenheimer, MD, FACAAI
Moderator:
Dana V. Wallace, MD, FACAAI
Speaker:
Matthew Greenhawt, MD, MSc, MBA, FACAAI
Speaker:
Matthew Rank, MD, FACAAI
Speaker:
Edmond S. Chan, MD
|
Food & Drug Allergy and GI Disorders
|
Practical Applications at Work Seminar
|
4:30 PM - 5:30 PM
|
Distinguished Industry Oral Abstracts With Refreshments: Session A
Not For Credit
Moderators: Brian T. Kelly, MD, FACAAI, and David R. Stukus, MD, FACAAI
4:30 pm
Welcome and Introductions
Brian T. Kelly, MD, MA
David R. Stukus, MD, FACAAI
4:35 pm
D200 – Relationship Between Systemic Corticosteroid Use, Associated Complications, and Health Care Costs in Patients with Persistent Asthma
James L. Kreindler, MD
4:45 pm
D201 – Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-severe Asthma and Serologic Evidence of Allergic Bronchopulmonary Aspergillosis
Jonathan Corren, MD, FACAAI
4:55 pm
D202 – Rescue Medication Use and Inhalation Patterns During Asthma Exacerbations Recorded by Digihaler
Roy Pleasants, PharmD
5:05 pm
D450 – Omalizumab Efficacy and Safety in Nasal Polyposis: Results From Two Parallel, Double-blind, Placebo-controlled trials
Philippe Gevaert, MD, PhD
5:15 pm
D451 – Clinical Activity of AK002, an Anti-Siglec-8 Antibody, in Severe Allergic Conjunctivitis and Comorbid Atopic Diseases
Terry Levine, MD
|
|
Moderator:
Brian T. Kelly, MD, MA
Moderator:
David R. Stukus, MD, FACAAI
|
|
Oral Abstract
|
Distinguished Industry Oral Abstracts With Refreshments: Session B
Not For Credit
Moderators: Lisa J. Kobrynski, MD, MPH, FACAAI, and Janna M. Tuck, MD, FACAAI
4:30 pm
Welcome and Introductions
Lisa R. Kobrynski, MD, MPH, FACAAI
Janna Tuck, MD, FACAAI
4:35 pm
D100 – CDX-0159, An Anti-KIT Monoclonal Antibody, As a Modulator of Mast Cellrelated Diseases
Diego Alvarado, PhD
4:45 pm
D301 – Etokimab Monotherapy in Peanutallergic Participants: A Proof of Concept Study
Sayantani (Tina) Sindher, MD
4:55 pm
D300 – Patient Experiences Following the OLFUS VIPES Phase IIb Epicutaneous Immunotherapy Trial: A Retrospective Qualitative Study
Terri Brown-Whitehorn, MD
5:05 pm
D302 – Perceptions Among Peanut-allergic Children: A Survey
Matthew Greenhawt, MD, MBA, MSc, FACAAI
5:15 pm
D303 – Improvements in Quality of Life Following Epicutaneous Peanut Immunotherapy: PEPITES and PEOPLE Studies
Audrey Dunn Galvin, PhD
|
|
Moderator:
Lisa J. Kobrynski, MD, MPH, FACAAI
Moderator:
Janna M. Tuck, MD, FACAAI
|
|
Oral Abstract
|
5:30 PM - 7:30 PM
|
28th Annual FIT Bowl Competition
Supported by DBV Technologies
Not For Credit
Test your knowledge, sharpen your wits and join in the fun at the dynamic, fast-paced FIT Bowl! Participating teams from training programs around the country will compete to answer a variety of serious (and not so serious) questions posed by an expert panel. Approximately 30 teams from the US and Mexico will participate in this popular game show. |
|
|
|
|
8:00 PM - 10:00 PM
|
Non-CME Corporate Forum: Dialogues in Asthma Patient Care: The Role of Digitally Connected Inhalers and Objective Inhaler Use Data
Supported by Teva Pharmaceuticals
Not For Credit
Presented by:
Gregory W. Bensch, MD
Nabeel Farooqui, MD
Warner W. Carr, MD
Maeve O’Connor, MD
Join an expert panel for an interactive program about the use of digital technology and the role of objective inhaler use data in asthma patient care. Learn about how inhaler use data may inform patient consultations. Attendees may also engage in a hands-on demonstration of an e-connected inhaler.
Also, visit Teva Pharmaceuticals at Booth #113. |
|
|
|
|
Non-CME Corporate Forum: The Allergic Asthma Challenge
Supported by Genentech and Novartis Pharmaceuticals Corporation
Not For Credit
Presented by:
Thomas B. Casale, MD
Jonathan Corren, MD
Test your asthma knowledge! The Allergic Asthma Challenge gives you an opportunity to compete against your colleagues in a trivia format. Questions and educational content will focus on asthma phenotypes and endotypes, asthma biomarkers, and the role of IgE in allergic asthma. We look forward to seeing you there!
Also, visit Genentech and Novartis Pharmaceuticals Corporation at Booth #713. |
|
|
|
|
Non-CME Corporate Forum: The Role of Eosinophils and Their Potential Heterogeneity in Airways Disease
Supported by GlaxoSmithKline
Not For Credit
Presented by:
Nicola Hanania, MD
Nestor Molfino, MD
Eosinophils play an important role in airways inflammation and proposed phenotypes in asthma and COPD. This program will review the biology of eosinophils and cellular-mediated mechanisms of airway inflammation. Use of eosinophils to identify subpopulations as well as guideline recommendations for incorporation of phenotyping into clinical practice will be highlighted.
Also, visit GlaxoSmithKline at Booth #1012. |
|
|
|
|